Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Nature Medicine

• Publication date

  2001-08-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1038/91000PMID 11479629
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions

  2001cited by this paper
• Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene.

  2001cited by this paper
• FADD Is Required for DR4- and DR5-mediated Apoptosis

  2000cited by this paper
• TRAIL receptor-2 signals apoptosis through FADD and caspase-8

  2000cited by this paper
• Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy.

  2000cited by this paper
• Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand

  2000cited by this paper
• Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5.

  2000cited by this paper
• FADD Is Required for DR 4-and DR 5-mediated Apoptosis LACK OF TRAIL-INDUCED APOPTOSIS IN FADD-DEFICIENT MOUSE EMBRYONIC FIBROBLASTS

  2000cited by this paper
• FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2.

  2000cited by this paper
• JNK/SAPK activity contributes to TRAIL-induced apoptosis

  1999cited by this paper
• Functional analysis of TRAIL receptors using monoclonal antibodies.

  1999cited by this paper
• TRAIL induces apoptosis and activation of NFkB.

  1999cited by this paper
• TRAIL causes cleavage of bid by caspase-8 and loss of mitochondrial membrane potential resulting in apoptosis in BJAB cells.

  1999cited by this paper
• Safety and antitumor activity of recombinant soluble Apo2 ligand.

  1999cited by this paper
• Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo

  1999cited by this paper
• TRAIL/Apo2L Activates c-Jun NH2-terminal Kinase (JNK) via Caspase-dependent and Caspase-independent Pathways*

  1998cited by this paper
• Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL*

  1998cited by this paper
• TRAIL induces apoptosis and activation of NFkappaB.

  1998cited by this paper
• Dominant-negative FADD inhibits TNFR60-, Fas/Apo1- and TRAIL-R/Apo2-mediated cell death but not gene induction.

  1998cited by this paper
• The Receptor for the Cytotoxic Ligand TRAIL

  1997cited by this paper
• Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors.

  1997cited by this paper
• TRAIL‐R2: a novel apoptosis‐mediating receptor for TRAIL

  1997cited by this paper
• The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain.

  1997cited by this paper
• TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB.

  1997cited by this paper
• Cloning and Characterization of TRAIL-R3, a Novel Member of the Emerging TRAIL Receptor Family

  1997cited by this paper
• Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway.

  1997cited by this paper
• An antagonist decoy receptor and a death domain-containing receptor for TRAIL.

  1997cited by this paper
• Identification and characterization of a new member of the TNF family that induces apoptosis.

  1995cited by this paper

• Immunoglobulin-Directed Phase Separation for Cell-Specific Modulation of Receptor Signaling.

  2025cites this paper
• Cytotoxic IgG: Mechanisms, functions, and applications.

  2025cites this paper
• Advances in the study of death receptor 5

  2025cites this paper
• DR5 CAR-NK Cells Demonstrate Superior Scalability and Potent Antitumor Activity with Favorable Safety.

  2025cites this paper
• TNF-Related Apoptosis-Inducing Ligand: Non-Apoptotic Signalling

  2024cites this paper
• Principles and therapeutic applications of adaptive immunity.

  2024cites this paper
• Chemical synthetic approaches to mimic the TRAIL: promising cancer therapeutics.

  2024cites this paper
• SH003 Induces DR5-Mediated Caspase-Dependent Apoptosis of NSCLC Through Inhibition of AKT Survival Pathway

  2024cites this paper
• MiR-29 and MiR-140 regulate TRAIL-induced drug tolerance in lung cancer

  2024cites this paper
• Nanoparticle-mediated gene delivery of TRAIL to resistant cancer cells: A review

  2024cites this paper
• Peg-lipid-modified agonistic antibody against tumor necrosis factor receptor family elicits superior apoptosis-inducing activity against human carcinoma.

  2024cites this paper
• Celastrol enhances TRAIL‑R2‑mediated apoptosis and cytotoxicity in human renal cell carcinoma cells in caspase‑dependent manner.

  2023cites this paper
• A Phase Separation-Fortified Bi-Specific Adaptor for Conditional Tumor Killing

  2023cites this paper
• Nanotechnology-empowered strategies in treatment of skin cancer.

  2023cites this paper
• Inhibition of liver fibrosis by sensitization of human hepatic stellate cells by combined treatment with galtanin and TARIL

  2023cites this paper
• Targeting Apoptosis in Cancer

  2022cites this paper
• Harnessing TRAIL-induced cell death for cancer therapy: a long walk with thrilling discoveries

  2022cites this paper
• TRAIL/S-layer/graphene quantum dot nanohybrid enhanced stability and anticancer activity of TRAIL on colon cancer cells

  2022cites this paper
• A Magainin-2 like bacteriocin BpSl14 with anticancer action from fish gut Bacillus safensis SDG14.

  2021cites this paper
• An anti-DR5 antibody-curcumin conjugate for the enhanced clearance of activated hepatic stellate cells.

  2021cites this paper
• Multimeric Anti-DR5 IgM Agonist Antibody IGM-8444 Is a Potent Inducer of Cancer Cell Apoptosis and Synergizes with Chemotherapy and BCL-2 Inhibitor ABT-199

  2021cites this paper
• sDR5-Fc inhibits macrophage M1 polarization by blocking the glycolysis

  2021cites this paper
• External stimuli-responsive nanomedicine for cancer immunotherapy

  2021cites this paper
• Harnessing TRAIL-Induced Apoptosis Pathway for Cancer Immunotherapy and Associated Challenges

  2021cites this paper
• BH3-only protein expression determines hepatocellular carcinoma response to sorafenib-based treatment

  2021cites this paper
• Single peptides and combination modalities for triple negative breast cancer

  2020cites this paper
• Enhancing the antitumor activity of an engineered TRAIL-coated oncolytic adenovirus for treating acute myeloid leukemia

  2020cites this paper
• Selective Tumor Cell Apoptosis and Tumor Regression in CDH17-Positive Colorectal Cancer Models using BI 905711, a Novel Liver-Sparing TRAILR2 Agonist

  2020cites this paper
• YIPF2 promotes chemotherapeutic agent-mediated apoptosis via enhancing TNFRSF10B recycling to plasma membrane in non-small cell lung cancer cells

  2020cites this paper
• Evaluation of the Cell Death Induction of Gold Nanoparticles Conjugated Antibodies Produced Against a Small Epitope of DR5 Protein in MCF7 Cells

  2019cites this paper
• Trimer form of tumor necrosis factor-related apoptosis inducing ligand induces apoptosis in canine cell lines derived from mammary tumors

  2019cites this paper
• Cytoplasmic PARP‐1 promotes pancreatic cancer tumorigenesis and resistance

  2019cites this paper
• Rapid and efficient cancer cell killing mediated by high-affinity death receptor homotrimerizing TRAIL

  2019cites this paper
• Understanding Apoptosis and Apoptotic Pathways Targeted Cancer Therapeutics

  2019cites this paper
• Cellular demolition: Proteins as molecular players of programmed cell death.

  2019cites this paper
• RUNX3 enhances TRAIL-induced apoptosis by upregulating DR5 in colorectal cancer

  2019cites this paper
• Involvement of p38 Activation and Mitochondria in Death of Human Leukemia Cells Induced by an Agonistic Human Monoclonal Antibody Fab Specific to TRAIL Receptor 1

  2019cites this paper
• TRAIL-based gene delivery and therapeutic strategies

  2019cites this paper
• Regulation of pancreatic cancer TRAIL resistance by protein O-GlcNAcylation

  2019cites this paper
• Calmodulin antagonist enhances DR5‐mediated apoptotic signaling in TRA‐8 resistant triple negative breast cancer cells

  2018cites this paper
• Should We Keep Walking along the Trail for Pancreatic Cancer Treatment? Revisiting TNF-Related Apoptosis-Inducing Ligand for Anticancer Therapy

  2018cites this paper
• Luminescent Iridium Complex-Peptide Hybrids (IPHs) for Therapeutics of Cancer: Design and Synthesis of IPHs for Detection of Cancer Cells and Induction of Their Necrosis-Type Cell Death

  2018cites this paper
• Developing TRAIL/TRAIL death receptor-based cancer therapies

  2018cites this paper
• From TRAIL to ONC201: Case Study on the Safety Benefit of Developing Targeted Agents Against Cancer-selective Pathways

  2018cites this paper
• Design and synthesis of a luminescent iridium complex-peptide hybrid (IPH) that detects cancer cells and induces their apoptosis.

  2018cites this paper
• N-glycosylation of mouse TRAIL-R restrains TRAIL-induced apoptosis

  2018cites this paper
• Präklinische Untersuchungen zum Einfluss von Wundauflagen aus bakteriellem Alginat auf Entzündungsmediatoren und Keiminaktivierung

  2018cites this paper
• Novel Immunoliposome Technology for Enhancing the Activity of the Agonistic Antibody against the Tumor Necrosis Factor Receptor Superfamily.

  2018cites this paper
• Maritoclax Enhances TRAIL-Induced Apoptosis via CHOP-Mediated Upregulation of DR5 and miR-708-Mediated Downregulation of cFLIP

  2018cites this paper
• Low-Dose Radiation Conditioning Enables CAR T Cells to Mitigate Antigen Escape.

  2018cites this paper
• Chimeric Mice With Humanized Livers Demonstrate Human-Specific Hepatotoxicity Caused by a Therapeutic Antibody Against TRAIL-Receptor 2/Death Receptor 5

  2018cites this paper
• Identification of Novel Epitopes with Agonistic Activity for the Development of Tumor Immunotherapy Targeting TRAIL-R1

  2017cites this paper
• Excess reactive oxygen species production mediates monoclonal antibody-induced human embryonic stem cell death via oncosis

  2017cites this paper
• A Novel Fully Human Agonistic Single Chain Fragment Variable Antibody Targeting Death Receptor 5 with Potent Antitumor Activity In Vitro and In Vivo

  2017cites this paper
• Enhancement of death receptor 4-mediated apoptosis and cytotoxicity in renal cell carcinoma cells by anisomycin

  2017cites this paper
• Optimizing Multistep Delivery of PEGylated Tumor-Necrosis-Factor-Related Apoptosis-Inducing Ligand-Toxin Conjugates for Improved Antitumor Activities.

  2017cites this paper
• Receptor-specific TRAIL as a means to achieve targeted elimination of activated hepatic stellate cells

  2017cites this paper
• Bi-specific molecule against EGFR and death receptors simultaneously targets proliferation and death pathways in tumors

  2017cites this paper
• Journey of TRAIL from Bench to Bedside and its Potential Role in Immuno-Oncology

  2017cites this paper
• Multivalent antibody-scTRAIL fusion proteins for tumor therapy : impact of format and targeting

  2017cites this paper
• The long non-coding RNA HOTAIR enhances pancreatic cancer resistance to TNF-related apoptosis-inducing ligand

  2017cites this paper
• Resistance to TRAIL Pathway-Targeted Therapeutics in Cancer

  2017cites this paper
• The apoptotic mechanisms of MT-6, a mitotic arrest inducer, in human ovarian cancer cells

  2017cites this paper
• Melanoma-directed activation of apoptosis using a novel bispecific antibody directed at MCSP and TRAIL receptor 2 / Death Receptor 5 CHAPTER 3

  2017cites this paper
• University of Groningen Trail receptor-targeted therapy : strategies to enhance DR 4-and DR 5-induced apoptosis

  2017cites this paper
• Melanoma-directed activation of apoptosis using a novel bispecific antibody directed at MCSP and TRAIL receptor 2/Death

  2017cites this paper
• Novel antibody-based drugs for PD-L1 and TRAIL-R targeted cancer immunotherapy

  2017cites this paper
• I mmunotherapy, M onoclonals, and V accines Chemotherapeutic Approaches for Targeting Cell Death Pathways

  2017cites this paper
• Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy

  2017cites this paper
• Calmodulin Binding to Death Receptor 5‐mediated Death‐Inducing Signaling Complex in Breast Cancer Cells

  2017cites this paper
• Antibodies and Derivatives Targeting DR4 and DR5 for Cancer Therapy

  2017cites this paper
• University of Groningen Receptor-specific TRAIL as a means to achieve targeted elimination of activated hepatic stellate cells

  2017cites this paper
• Structural Insight for Roles of DR5 Death Domain Mutations on Oligomerization of DR5 Death Domain–FADD Complex in the Death-Inducing Signaling Complex Formation: A Computational Study

  2016cites this paper
• New Frontiers in Cancer Chemotherapy — Targeting Cell Death Pathways

  2016cites this paper
• The intrinsically kinase-inactive EPHB6 receptor predisposes cancer cells to DR5-induced apoptosis by promoting mitochondrial fragmentation

  2016cites this paper
• DR5 mAb-conjugated, DTIC-loaded immuno-nanoparticles effectively and specifically kill malignant melanoma cells in vivo

  2016cites this paper
• Characterization of the Interactions between Calmodulin and Death Receptor 5 in Triple-negative and Estrogen Receptor-positive Breast Cancer Cells

  2016cites this paper
• Hyaluronate-Gold Nanorod/DR5 Antibody Complex for Noninvasive Theranosis of Skin Cancer.

  2016cites this paper
• Apoptotic Killing of Breast Cancer Cells by IgYs Produced Against a Small 21 Aminoacid Epitope of the Human TRAIL-2 Receptor.

  2016cites this paper
• Hyaluronate-Death Receptor 5 Antibody Conjugates for Targeted Treatment of Liver Metastasis.

  2016cites this paper
• A Novel Imaging Biomarker Extracted from Fluorescence Microscopic Imaging of TRA-8/DR5 Oligomers Predicts TRA-8 Therapeutic Efficacy in Breast and Pancreatic Cancer Mouse Models

  2016cites this paper
• Restoring TRAIL Induced Apoptosis Using Naturopathy. Hercules Joins Hand with Nature to Triumph Over Lernaean Hydra

  2016cites this paper
• Elimination of activated hepatic stellate cells by receptor-specific TRAIL

  2016cites this paper
• Cytotoxicity Effects of Mouse IgG Produced against Three Nanoliposomal Human DR5 Receptor Epitopes on Breast Cancer Cells.

  2016cites this paper
• Potential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand?

  2016cites this paper
• Flavonol and imidazole derivatives block HPV16 E6 activities and reactivate apoptotic pathways in HPV+ cells

  2016cites this paper
• In Vitro and In Vivo Evaluation of 89Zr-DS-8273a as a Theranostic for Anti-Death Receptor 5 Therapy

  2016cites this paper
• Secretory TRAIL-Armed Natural Killer Cell–Based Therapy: In Vitro and In Vivo Colorectal Peritoneal Carcinomatosis Xenograft

  2016cites this paper
• Targeting human carcinoma cells by receptor- specific TRAIL and Histone acetyl transferase / Deacetylase inhibitor regimens drives enhanced killing efficiency

  2016cites this paper
• Therapeutic strategies targeting Kv10.1 in PDAC

  2016cites this paper
• Onto better TRAILs for cancer treatment

  2016cites this paper
• Improved anti-tumor activity of oxaliplatin by encapsulating in anti-DR5 targeted gold nanoparticles

  2016cites this paper
• Analysis of aDR5scFv with Specific Identification and Function

  2016cites this paper
• Death Receptor 5 Networks Require Membrane Cholesterol for Proper Structure and Function.

  2016cites this paper
• Chapter 1 Application of tumor necrosis factor-related apoptosis-inducing ligand ( TRAIL ) for the treatment of liver fibrosis

  2016cites this paper
• Targeted radiotherapy potentiates the cytotoxicity of a novel anti-human DR5 monoclonal antibody and the adenovirus encoding soluble TRAIL in prostate cancer.

  2015cites this paper
• Trailing TRAIL Resistance: Novel Targets for TRAIL Sensitization in Cancer Cells

  2015cites this paper
• Natural killer cells in hepatitis B virus infection

  2015cites this paper
• Proteasomal inhibition sensitizes cervical cancer cells to mitomycin C-induced bystander effect: the role of tumor microenvironment

  2015cites this paper
• The novel proteasome inhibitor carfilzomib activates and enhances extrinsic apoptosis involving stabilization of death receptor 5

  2015cites this paper